Maria K Svensson, Toyoaki Murohara, Eva Lesén, Matthew Arnold, Thomas Cars, Krister Järbrink, Gengshi Chen, Naru Morita, Sudhir Venkatesan, Eiichiro Kanda
BACKGROUND: Hyperkalaemia is a barrier to achieving optimal, guideline-directed treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with chronic kidney disease (CKD) and/or heart failure (HF). This study describes the association between hyperkalaemia-related RAASi treatment reduction and number of hospitalized days in patients with CKD and/or HF in Sweden and Japan. METHODS: Using data from health registers and hospital medical records, patients with CKD and/or HF currently receiving RAASi who experienced an index hyperkalaemia episode were identified and categorized as having maintained or reduced RAASi treatment post-index; propensity-score matching (1:1) was applied to balance the groups in terms of baseline characteristics...
January 22, 2024: Nephrology, Dialysis, Transplantation